Compare IONQ Inc (IONQ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Novo Nordisk A/S — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 10.3× IONQ Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Novo Nordisk A/S for 116 Days on average.
| IONQ | NVO | |
|---|---|---|
Market Cap | $15.98B | $165.31B |
Volume | 22,848,240 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $82.09 | $63.98 |
52-Week Low | $26.59 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $13.92B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.45, down 4.57% today, showing bearish technical signals with mixed fundamental performance. The company reported strong revenue growth ($130M in 2025, projected $246M in 2026) but significant losses (-$510M net income in 2025). Recent earnings show a pattern of beats and misses, with Q2 2026 missing expectations. Technical indicators show bearish momentum despite some oversold conditions, with key support at $36 and resistance at $41.
Outlook remains speculative with high growth potential but substantial execution risks. Analyst consensus is split with a $62.75 price target suggesting 59% upside, though profitability challenges and cash burn (-$283M operating cash flow in 2025) present significant hurdles. The quantum computing market opportunity is substantial, but IONQ must demonstrate path to profitability to justify current valuations.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
